Tag: SELECT trial
-
Beyond weight loss: How Semaglutide cuts heart risk faster than the scale moves
Introduction: The heart benefits most patients want Semaglutide, a medication originally developed to help manage type 2 diabetes and support weight loss, has found a broader role in cardiovascular health. While the scale may take time to show dramatic change, researchers and clinicians are discovering that semaglutide can lower heart risk parameters sooner than expected.…
-
Beyond weight loss: Semaglutide cuts heart risk faster than the scale moves
Introduction: A drug with dual promise Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has long been a staple in the toolbox for managing type 2 diabetes and supporting weight loss. But a growing body of evidence suggests its benefits extend beyond body mass, targeting cardiovascular risk in meaningful ways. The SELECT trial, in particular, has…